Colorectal

Most recent

Predictive value of skin toxicity and panitumumab efficacy

NE Oncology Issue - June 2007 Background Skin toxicities are a common side effect with EGFR inhibitor treatment. Results from the pivotal phase III trial for cetuximab indicate that there may be a physiologic correlation between the onset of skin toxicity and...

Canadian perspective by Dr. Cripps

NE Oncology Issue - June 2007 The data from the presentations at ASCO indicate that panitumumab is certainly very similar to cetuximab with regards to the efficacy and side effects profile. Panitumumab has the added advantage of slightly lower side effects and...

Twitter feed

RT @NatureNews: In the age of immunotherapy, cancer biologists are relying on a new generation of tools to learn how the interplay between…
h J R
Video: Dr. Mark Vincent Discusses Outcomes in Pancreatic Adenocarcinoma Patients with Genetic Alterations in DNA Da… https://t.co/35E7MSeX3V
h J R
RT @medoncdoc: CO26. first evidence of survival benefit in MSS patients using immunotherapy. 6.6 mo vs 4.1 mo.#GI19 @CDNCancerTrials great…
h J R
RT @tehfem: Adjuvant HIPEC in CRC at high risk for peritoneal mets No benefit #GI19 https://t.co/tYIw9B3eme
h J R
RT @GillSharlene: How long to optimally wait for resection after neoadjuvant therapy for early stage rectal cancer? Looks like the answer…
h J R

Other

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Twitter feed

RT @NatureNews: In the age of immunotherapy, cancer biologists are relying on a new generation of tools to learn how the interplay between…
h J R
Video: Dr. Mark Vincent Discusses Outcomes in Pancreatic Adenocarcinoma Patients with Genetic Alterations in DNA Da… https://t.co/35E7MSeX3V
h J R
RT @medoncdoc: CO26. first evidence of survival benefit in MSS patients using immunotherapy. 6.6 mo vs 4.1 mo.#GI19 @CDNCancerTrials great…
h J R
RT @tehfem: Adjuvant HIPEC in CRC at high risk for peritoneal mets No benefit #GI19 https://t.co/tYIw9B3eme
h J R
RT @GillSharlene: How long to optimally wait for resection after neoadjuvant therapy for early stage rectal cancer? Looks like the answer…
h J R